Tyto Care Launches AI-Powered Diagnostic Support Solution

Amwell, Tyto Care Expand Partnership to Power Augmented Virtual Care Experiences
Amwell, Tyto Care Expand Partnership to Power Augmented Virtual Care Experiences

What You Should Know:

– Today, Tyto Care announced the company’s evolution from
telehealth to tele-diagnosis with its AI-powered diagnostic support solution,
providing clinicians with advanced insights for informed remote diagnoses. 

– The solution will improve the quality of remote triage
for common primary and chronic health issues – starting with wheezing and
stridor – grounded in Tyto Care’s industry-leading repository of remote exam
videos, sounds and images.


Tyto Care, a New York City-based all-in-one modular device and examination platform for AI-powered, on-demand, remote medical exams, today announced its AI-powered diagnostic support solution, providing clinicians with advanced insights for informed remote diagnoses. The solution will improve the quality of remote triage for common primary and chronic health issues, grounded in Tyto Care’s industry-leading repository of videos, sounds, and images related to telehealth visits. The diagnostic tool has been submitted to the FDA for clearance, expected in mid-2021. 

Tyto Care developed the decision support tool in conjunction
with experienced pulmonologists and general practitioners based on its vast
database of insights. Since receiving FDA clearance for the TytoCare device in
2017, the company has accumulated a powerful repository of clinical exams,
including over 450,000 exams performed in the past 12 months.


AI-Powered Diagnostic Support Solution

Using machine learning algorithms, the diagnostic support
solution will have numerous applications, initially deploying to detect
abnormalities in lung exams such as wheezing, stridor and crackles, with plans
to detect symptoms in throat exams such as exudates, throat redness and swollen
tonsils. The new Tyto Care solution will alert clinicians and patients to the
presence of these abnormalities, providing clinicians much-needed decision
support for common use cases. Wheezing, for example, has a high frequency of
cases but a low rate of remote diagnosis by general practitioners. The ability
to provide clinicians with expanded throat and lung insights is especially
crucial during the COVID-19
pandemic.

Analysis of this robust big data, in combination with
clinical literature, fuels the decision support algorithms. The algorithms,
which required testing on the large number of exam recordings unique to Tyto
Care, are also uniquely equipped to handle lower quality data collected during
user intake exams and to remove any interfering sounds. Tyto Care chose lung
abnormalities for its initial use case due to the widespread success of its
lung exam.

The AI-powered
diagnostic solution follows Tyto Care’s existing AI-guidance tool, which
enables the replication of in-person visits by guiding users to accurately
collect exam data, and further digitizes the entire primary care journey for
patients and clinicians alike. Moving toward tele-diagnosis, Tyto Care plans to
expand future at-home use cases with self-diagnosis, remote monitoring and
remote lab capabilities. 


“We are excited to be pushing forward the evolution from telehealth to tele-diagnosis,” said Dedi Gilad, CEO and Co-Founder of Tyto Care. “The pandemic has accelerated the need for remote care, and we have seen firsthand the global surge in demand from health organizations, hospitals and consumers for high-quality telehealth solutions. With Tyto’s diagnosis support solution, we will be equipping clinicians to make better informed decisions from afar. We look forward to propelling telehealth and tele-diagnosis even further with other at-home diagnosis solutions to come.”


<!–

–>